---
title: "ARS Pharmaceuticals, Inc. (SPRY.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/SPRY.US.md"
symbol: "SPRY.US"
name: "ARS Pharmaceuticals, Inc."
industry: "生物技术"
---

# ARS Pharmaceuticals, Inc. (SPRY.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [ars-pharma.com](https://ars-pharma.com) |

## Company Profile

ARS Pharmaceuticals, Inc.是一家生物制药公司，专注于开发和商业化严重过敏反应的治疗方案。该公司正在开发 neffy，这是一种无针和低剂量的鼻用肾上腺素喷雾剂，用于救援治疗 I 型严重过敏反应患者，包括过敏性休克。它为医疗专业人员、患者和护理人员提供服务。该公司成立于 2015 年，总部位于加利福尼亚州圣地亚哥

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:14.000Z

**Overall: C (0.50)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 105 / 399 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5459.66% |  |
| Net Profit YoY | -63.00% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 6.33 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 934.12M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 142.77M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -45.92% | E |
| Profit Margin | -56.06% | E |
| Gross Margin | 66.33% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 5459.66% | A |
| Net Profit YoY | -63.00% | D |
| Total Assets YoY | 71.32% | A |
| Net Assets YoY | -26.53% | E |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -178.38% | D |
| OCF YoY | 5459.66% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.48 | C |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 60.39% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - ARS Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-45.92%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-56.06%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "66.33%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "5459.66%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-63.00%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "71.32%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-26.53%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-178.38%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "5459.66%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.48",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "60.39%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -11.67 | 459/603 | 176.41 | 165.50 | 157.40 |
| PB | 6.33 | 329/603 | 7.33 | 6.05 | 5.12 |
| PS (TTM) | 6.54 | 120/603 | 16.85 | 12.24 | 7.36 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-02T05:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 6 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 9.45 |
| Highest Target | 39.00 |
| Lowest Target | 12.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/SPRY.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/SPRY.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/SPRY.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.